pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,224 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints893BioPharma Dive344BioSpace310Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7617Rare Disease1875Cardiology1743Immunology1482Hematology1323Vaccines1197Pulmonology
  • The ‘velocity of obesity’ aims to show which nations are slowing an epidemic
    A study finds the rise in U.S. obesity rates have hit a plateau in children but are still climbing for adults, and are still high compared to those in other…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Hospitals restricting doctors' social media posts may worsen health misinformation, says physician
    Adam Goodcoff, chief medical officer at HealthCentral, began creating health content online while in medical school, using short videos to explain procedures and counter myths, such as the depth of…
    STAT · 3mo agoNegative↗ source
← prev
page 79 of 89
next →
fda recalls70
fda medwatch60
fda press38
1188
Psychiatry & CNS866
Ophthalmology496
Pain480
Endocrinology & Metabolism474
Infectious Disease444
  • CMS pauses enrollment of new hospice and home health providers for six months
    CMS announced a six-month moratorium on enrolling new hospice and home health agencies. The pause is part of the Trump administration's broader effort to curb fraud, waste, and abuse in Medicare s…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • STAT+ reveals hidden issues in FDA's AI medical device approval pathway
    Brittany Trang, a health‑tech reporter, published a STAT+ newsletter piece that examines how the FDA handles AI‑driven medical devices. The article highlights the lack of transparency in the agency…
    STAT · 3mo agoNegative↗ source
  • FDA commissioner resigns as Marty Makary steps down, Bill Cassidy faces tough primary
    The newsletter highlights that extreme heat is worsening faster for Black Americans, underscoring a growing health disparity. FDA Commissioner Marty Makary resigned yesterday, and Kyle Diamantas,…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • RFK Jr.’s antidepressant deprescribing campaign praised for awareness but flagged as unsafe without proper support
    A clinical professor of psychiatry at Columbia University writes that Robert F. Kennedy Jr.'s push to deprescribe antidepressants raises public attention but lacks the clinical infrastructure neede…
    STAT · 3mo agoNegative↗ source
  • Sen. Bill Cassidy’s impeachment vote and RFK Jr. confirmation jeopardize his political future
    Sen. Bill Cassidy, a former physician turned lawmaker, has taken political actions that threaten his standing in Louisiana. He voted to impeach former President Donald Trump and supported the confi…
    STAT · 3mo agoNegative↗ source
  • CDC says hantavirus risk to public remains low despite cruise ship outbreak
    Two CDC doctors told reporters the risk of hantavirus to the general public is low and that the agency is engaged at every step of the response. They outlined a coordinated effort that includes st…
    STAT · 3mo agoNeutral↗ source
  • Podcast explores the limits of "blue zones" concept in aging research
    On a recent First Opinion podcast, medical journalist Shelley Wood and cardiologist Eric Topol discussed the "blue zones" concept and its relevance to aging research. They traced the idea back to…
    STAT · 3mo agoNeutral↗ source
  • Bristol Myers Squibb signs up to $15.2 billion partnership with China's Hengrui Pharma
    Bristol Myers Squibb announced a licensing partnership with China's Hengrui Pharma covering more than a dozen early-stage drug programs. The agreement includes a $600 million upfront payment to He…
    STAT · 4mo agoDealPositive↗ source
  • FDA chief Marty Makary resigns, ending turbulent tenure
    FDA chief Marty Makary has resigned, ending a tenure described as turbulent with leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers. President Trump announce…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • Bristol Myers Squibb and China's Hengrui Pharma launch $15.2 billion alliance covering up to 13 early-stage drugs
    Bristol Myers Squibb announced a new partnership with Chinese drugmaker Hengrui Pharma that could be worth more than $15.2 billion and includes up to 13 early-stage drug candidates. The deal refle…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Alcohol epidemic claims nearly 500 U.S. lives daily, exposing systemic public-health failures
    The investigative series "The Deadliest Drug" surveyed more than 100 health researchers, clinicians, patients, industry insiders and lawmakers, and examined scientific literature, treatment protoco…
    STAT · 3mo agoNegative↗ source
  • Supreme Court grants three-day extension on ruling over abortion drug mifepristone
    The U.S. Supreme Court announced it will take an additional three days before issuing a decision in the case concerning the abortion medication mifepristone. The case, Louisiana v. FDA, reached th…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Pain drug research gains momentum a year after Vertex launch as new startups revive sodium channel targets
    A year after Vertex introduced its breakthrough pain medication, the field of pain drug development is at a pivotal crossroads. Analysts note that renewed scientific focus and investor interest are…
    BioPharma Dive · 3mo agoPositive↗ source
  • Pharma leaders risk industry collapse by over-relying on Chinese drug sourcing, says analyst
    Olivia Kosloff, a senior fellow at the American Economic Liberties Project and co-chair of a Council on Foreign Relations working group, argues that U.S. pharma and biotech executives are jeopardiz…
    STAT · 3mo agoNegative↗ source
  • Former FDA Commissioner Marty Makary resigns under pressure, critics call his tenure the weakest in 25 years
    Marty Makary stepped down as FDA commissioner on Tuesday after mounting pressure, ending a tenure that many observers described as the weakest in the agency’s recent history. Critics said he lacke…
    STAT · 3mo agoRegulatoryNegative↗ source
  • EU drafts Critical Medicines Act to increase local production and curb drug shortages
    The European Union has reached a provisional agreement known as the Critical Medicines Act, aimed at strengthening the supply of essential medicines across member states. The plan focuses on incre…
    STAT · 3mo agoRegulatoryPositive↗ source
  • FDA Commissioner Marty Makary resigns amid internal turmoil, top food regulator Kyle Diamantas to serve as acting chief
    Food and Drug Administration Commissioner Marty Makary is leaving his post after serving a little over a year, according to an administration source. His tenure was marked by staff departures and i…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Hims sales dip as telehealth rivals intensify; Bristol partners with Chinese firm, other biotech updates
    Hims reported lower sales this quarter, attributing the shortfall to growing competition from other telehealth providers. Bristol announced a new partnership with Chinese drugmaker Hengrui Pharma…
    STAT · 3mo agoNeutral↗ source
  • Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel Pharmaceuticals
    Arvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Capsida Biotherapeutics still unable to determine cause of child death in brain-targeted gene therapy trial
    Capsida Biotherapeutics reported that it still has no explanation for the death of a child who participated in its CAP-002 gene therapy trial last September. The trial was intended to test a new c…
    STAT · 3mo agoNegative readoutNegative↗ source
  • Alcohol Remains U.S. Deadliest Drug, Killing 178,000 Annually, Study Finds
    STAT’s investigative series "The Deadliest Drug" catalogues the United States' failure to address excessive alcohol use as a leading cause of disease, injury and death. Even as overall drinking ra…
    STAT · 3mo agoNegative↗ source
  • Pharma firms spend $130M lobbying on TrumpRx plan, while Novo Nordisk reports 27.7% weight loss in high‑dose Wegovy trial
    Seventeen pharmaceutical companies that back the White House’s TrumpRx prescription‑drug pricing program collectively spent more than $130 million on federal lobbying in 2025. That represents a ro…
    STAT · 3mo agoNeutral↗ source
  • Hims reports $33 million loss after shifting focus to GLP-1 market
    Hims said its latest earnings were hit by a $33 million charge tied to a strategic shift toward GLP-1 treatments. The charge stems from costs of redirecting product development and marketing resou…
    STAT · 3mo agoEarningsNegative↗ source